| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CPT.318 |
| P8608 | Fatcat ID | release_2wsgazkz4rfkrj434ba5gz23bu |
| P3181 | OpenCitations bibliographic resource ID | 1691237 |
| P932 | PMC publication ID | 4785018 |
| P698 | PubMed publication ID | 26659699 |
| P2093 | author name string | B Chen | |
| A J Butte | |||
| P2860 | cites work | Cancer genome landscapes | Q22242276 |
| International network of cancer genome projects | Q24611474 | ||
| DrugBank 3.0: a comprehensive resource for 'omics' research on drugs | Q24612505 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Predicting new molecular targets for known drugs | Q24649687 | ||
| Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality | Q24745996 | ||
| Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference | Q26852489 | ||
| Preclinical mouse cancer models: a maze of opportunities and challenges | Q27322080 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions | Q28550159 | ||
| Public data and open source tools for multi-assay genomic investigation of disease | Q28596241 | ||
| Genetics of rheumatoid arthritis contributes to biology and drug discovery | Q29417000 | ||
| Network medicine: a network-based approach to human disease | Q29547462 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| A new initiative on precision medicine | Q29615654 | ||
| A draft map of the human proteome | Q29617250 | ||
| Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. | Q30384542 | ||
| Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease | Q30526431 | ||
| Biology: The big challenges of big data | Q30647898 | ||
| Inferring tumour purity and stromal and immune cell admixture from expression data | Q30674996 | ||
| Raw data from clinical trials: within reach? | Q30705429 | ||
| Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov | Q30884583 | ||
| Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research | Q30965534 | ||
| Identification of small molecules enhancing autophagic function from drug network analysis | Q33712703 | ||
| HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells | Q33760690 | ||
| A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma | Q33854958 | ||
| Computational repositioning and preclinical validation of pentamidine for renal cell cancer. | Q33875574 | ||
| Discovery and preclinical validation of drug indications using compendia of public gene expression data | Q33995422 | ||
| Identification and characterization of essential genes in the human genome. | Q34045164 | ||
| Discovery of drug mode of action and drug repositioning from transcriptional responses | Q34093341 | ||
| Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin | Q34131764 | ||
| Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer | Q34135362 | ||
| MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival | Q34177820 | ||
| Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib | Q34191711 | ||
| Essential gene profiles in breast, pancreatic, and ovarian cancer cells. | Q34268870 | ||
| Comparing bioinformatic gene expression profiling methods: microarray and RNA-Seq | Q34434633 | ||
| In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities | Q34466574 | ||
| A systematic assessment of linking gene expression with genetic variants for prioritizing candidate targets | Q34988225 | ||
| A guide to drug discovery: Target selection in drug discovery | Q35037671 | ||
| Exploiting drug-disease relationships for computational drug repositioning | Q35109885 | ||
| The Comparative Toxicogenomics Database's 10th year anniversary: update 2015. | Q35254732 | ||
| A community computational challenge to predict the activity of pairs of compounds | Q35446621 | ||
| Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. | Q35531740 | ||
| Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies | Q35609041 | ||
| The support of human genetic evidence for approved drug indications | Q35677036 | ||
| Elucidating Compound Mechanism of Action by Network Perturbation Analysis. | Q35694439 | ||
| Subtype and pathway specific responses to anticancer compounds in breast cancer | Q35779241 | ||
| Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes | Q35935710 | ||
| Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models. | Q36113762 | ||
| Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. | Q36139333 | ||
| Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway | Q36179224 | ||
| Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records | Q36972534 | ||
| Evaluating cell lines as tumour models by comparison of genomic profiles | Q37025950 | ||
| A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation | Q37246506 | ||
| Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas | Q37281335 | ||
| Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer | Q37331472 | ||
| A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. | Q37395737 | ||
| Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. | Q37411227 | ||
| A comprehensive transcriptional portrait of human cancer cell lines | Q37854720 | ||
| Validating therapeutic targets through human genetics | Q38122628 | ||
| An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. | Q38275613 | ||
| Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma. | Q39104237 | ||
| canSAR: an integrated cancer public translational research and drug discovery resource | Q39455504 | ||
| Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia | Q40764658 | ||
| Network medicine in disease analysis and therapeutics | Q41890269 | ||
| Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling | Q42704783 | ||
| Objective assessment of cancer genes for drug discovery | Q57001160 | ||
| Reproducibility crisis: Blame it on the antibodies | Q59060328 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| big data | Q858810 | ||
| drug discovery | Q1418791 | ||
| precision medicine | Q17075943 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 285-97 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Leveraging big data to transform target selection and drug discovery | |
| P478 | volume | 99 |
| Q92328880 | A Pathway-Based Genomic Approach to Identify Medications: Application to Alcohol Use Disorder |
| Q42698699 | A Review of Recent Advances in Translational Bioinformatics: Bridges from Biology to Medicine. |
| Q98784944 | ADRML: anticancer drug response prediction using manifold learning |
| Q92320711 | AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets |
| Q114871132 | Application of Artificial Intelligence in Discovery and Development of Anticancer and Antidiabetic Therapeutic Agents |
| Q64988161 | Artificial Intelligence and Personalized Medicine. |
| Q28591396 | BIGCHEM: Challenges and Opportunities for Big Data Analysis in Chemistry |
| Q89875046 | Bayesian Framework for Detecting Gene Expression Outliers in Individual Samples |
| Q35926778 | Big Data Transforms Discovery-Utilization Therapeutics Continuum. |
| Q91117785 | Big data in IBD: a look into the future |
| Q31141724 | Clinical Research Informatics for Big Data and Precision Medicine |
| Q38598719 | Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity in transcriptional responses |
| Q26746941 | Computational approaches in target identification and drug discovery |
| Q96836052 | Concise Polygenic Models for Cancer-Specific Identification of Drug-Sensitive Tumors from Their Multi-Omics Profiles |
| Q93086929 | Creating reproducible pharmacogenomic analysis pipelines |
| Q89928441 | Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology |
| Q58552664 | Developments with 3D bioprinting for novel drug discovery |
| Q64915233 | Differential Expression and Pathway Analysis in Drug-Resistant Triple-Negative Breast Cancer Cell Lines Using RNASeq Analysis. |
| Q36315748 | Ethics and Epistemology in Big Data Research |
| Q52316006 | From gene networks to drugs: systems pharmacology approaches for AUD. |
| Q52580320 | Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease. |
| Q28551995 | Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the Comparative Toxicogenomics Database |
| Q50083199 | Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies |
| Q47910117 | Genome-Wide Expression Profiles Drive Discovery of Novel Compounds that Reduce Binge Drinking in Mice. |
| Q92407464 | Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma |
| Q30491667 | Harnessing public domain data to discover and validate therapeutic targets |
| Q38646272 | Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. |
| Q93061511 | In Silico Toxicology Data Resources to Support Read-Across and (Q)SAR |
| Q39039446 | Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases. |
| Q36946947 | Isolation of the Binding Protein of Periplocoside E from BBMVs in Midgut of the Oriental Amyworm Mythimna separata Walker (Lepidoptera: Noctuidae) through Affinity Chromatography |
| Q52681322 | It is time to apply biclustering: a comprehensive review of biclustering applications in biological and biomedical data. |
| Q64086525 | Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer |
| Q36229691 | Macromolecular target prediction by self-organizing feature maps |
| Q64081579 | Metascape provides a biologist-oriented resource for the analysis of systems-level datasets |
| Q64119088 | Mining data and metadata from the gene expression omnibus |
| Q47366650 | Molecular property diagnostic suite (MPDS): Development of disease-specific open source web portals for drug discovery. |
| Q60953364 | Persistence of Drug Memories: Melting Transcriptomes |
| Q56961708 | Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling |
| Q33903831 | Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets |
| Q93116011 | Signaling pathways and gene co-expression modules associated with cytoskeleton and axon morphology in breast cancer survivors with chronic paclitaxel-induced peripheral neuropathy |
| Q92547592 | Systems pharmacology-based integration of human and mouse data for drug repurposing to treat thoracic aneurysms |
| Q36391199 | The Utility of Gene Expression Profiling from Tissue Samples to Support Drug Safety Assessments |
| Q39029383 | The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies |
| Q47116549 | Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics |
| Q47226520 | Translating Knowledge Into Therapy for Acute Kidney Injury |
| Q47732489 | Update on Data Reuse in Health Care |
| Q47252941 | gene2drug: a Computational Tool for Pathway-based Rational Drug Repositioning |
Search more.